TwinBeech Capital’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

TwinBeech Capital’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,820	Closed	-$291K	–	783
2022 Q1	$291K	Buy	+10,820	New	+$364K	0.01%	429
2021 Q4	–	Sell	-18,039	Closed	-$1.2M	–	886
2021 Q3	$1.2M	Buy	+18,039	New	+$1.29M	0.08%	302
2021 Q2	–	Sell	-8,900	Closed	-$842K	–	714
2021 Q1	$842K	Buy	+8,900	New	+$1.06M	0.12%	216

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

TwinBeech Capital's TPTX Position: Q2 2022 in Review

TwinBeech Capital sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 10,820 shares — an estimated $291K sold.

TwinBeech Capital first reported a position in TPTX in Q1 2021 and held it in 3 quarters. The position peaked at $1.2M in Q3 2021. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

TwinBeech Capital reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
TwinBeech Capital sold 10,820 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $291K.
TwinBeech Capital first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
TwinBeech Capital's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.2M in Q3 2021.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on TwinBeech Capital's 13F filing for Q2 2022, filed 15 Aug 2022.